| AZ | EN | RU

СТАТИСТИКА

   Печать страницы             

ПРОГНОСТИЧЕСКИЕ ФАКТОРЫ ЗРЕНИЯ У ПАЦИЕНТОВ С ТРОМБОЗОМ ВЕН СЕТЧАТКИ ПОСЛЕ ИНТРАВИТРЕАЛЬНОЙ ИНЪЕКЦИИ
Казымова Л.А.

DOI: 10.61775/2413-3302.v2i32.06

РЕЗЮМЕ
В статье представлена корреляция остроты зрения, сниженная, в результате образования макулярного отека после тромбоза вен сетчатки (ТВС), и частично восстановленная после инъекционного лечения. Применен специальный метод для исследования нарушения целостности наружной пограничной мембраны (НПМ) на изображениях оптической когерентной томографии (ОКТ). Однофакторный и многомерный линейный регрессионный анализ был проведен для оценки взаимосвязи между остротой зрения до и после лечения. Было показано, что после лечения целостность НПМ является независимым и важным фактором в прогнозировании остроты зрения. При оценке зрительной функции у пациентов с макулярным отеком ТВС, после инъекций ранибизумаба, целостность НПМ, особенно ниже центра центральной ямки, может быть более полезной, чем другие факторы.
Keywords: целостность наружной пограничной мембраны, ранибизумаб, тромбоз вен сетчатки, острота зрения, ОКТ

ЛИТЕРАТУРА
  1. Huang P, Song Z, Sun X. Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion // Chin Med J (Engl) 2014;127:3019-3023.
  2. Huang P, Niu W, Ni Z, Wang R, Sun X. A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion // PLoS One. 2013;8:e82454. doi: 10.1371/journal.pone.0082454.
  3. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY. Natural history of central retinal vein occlusion: An evidence-based systematic review // Ophthalmology. 2010;117:1113-1123. doi: 10.1016/j.ophtha.2010.01.060.
  4. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY. Natural history of branch retinal vein occlusion: An evidence-based systematic review // Ophthalm., 2010;117:1094-1101. doi:10.1016/j.ophtha.2010.01. 058.
  5. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY. International eye disease consortium: The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia and Australia // Ophthalmology. 2010;117:313-319. doi: 10.1016/j.ophtha.2009.07.017.
  6. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion // Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
  7. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, Cruise Investigators Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study // Ophthalmology. 2010;117:1124-1133. doi: 10.1016/j.ophtha.2010.02.022.
  8. Demir M, Oba E, Gulkilik G, Odabasi M, Ozdal E. Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results // Clin Ophthalmol. 2011;5:745-749. doi: 10.2147/OPTH.S19279.
  9. Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions // Br J Ophthalmol. 2010;94:1052-1056. doi: 10.1136/bjo.2009.173732.
  10. Gallego-Pinazo R, Dolz-Marco R, Pardo-Lopez D, Martinez-Castillo S, Lleo-Perez A, Arevalo JF, Diaz-Llopis M. Ranibizumab for serous macular detachment in branch retinal vein occlusions // Graefes Arch Clin Exp Ophthalmol. 2013;251:9-14. doi: 10.1007/s00417-012-2023-7.
  11. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial // Br J Ophthalmol. 2009;93:452-456. doi: 10.1136/bjo.2008.141085.
  12. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion // Am J Ophthalmol. 2009;147:298-306. doi: 10.1016/j.ajo.2008.08.016.
  13. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW, Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion // Retina. 2009;29:913-925. doi: 10.1097/IAE.0b013e3181aa8dfe.
  14. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, Martin JF, Hykin PG. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion // Arch Ophthalmol. 2002;120:1644-1650. doi: 10.1001/archopht.120.12.1644.
  15. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study // Ophthalmology. 2011;118:2041-2049. doi: 10.1016/j.ophtha.2011.02.038.
  16. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study // Ophthalmology. 2010;117:1102-1112. doi: 10.1016/j.ophtha.2010.02.021.
  17. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study // Ophthalmology. 2014;121:209-219. doi: 10.1016/j.ophtha.2013.08.038.
  18. Glanville J, Patterson J, McCool R, Ferreira A, Gairy K, Pearce I. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: A systematic review // BMC Ophthalmol. 2014;14:7. doi: 10.1186/1471-2415-14-7.
  19. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene- Johansen I. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: Results from the sham-controlled ROCC study // Am J Ophthalmol. 2010;150:310-314. doi: 10.1016/j.ajo.2010.03.028.
  20. Regnier SA, Larsen M, Bezlyak V, Allen F. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: A network meta-analysis // BMJ Open. 2015;5:e007527. doi: 10.1136/bmjopen-2014-007527.
  21. Thom HH, Capkun G, Nixon RM, Ferreira A. Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion // BMC Med Res Methodol. 2014;14:140. doi: 10.1186/1471-2288-14-140.
  22. Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion // Invest Ophthalmol Vis Sci. 2011;52:3334-3337. doi: 10.1167/iovs.10-6097.
  23. Keane PA, Sadda SR. Predicting visual outcomes for macular disease using optical coherence tomography // Saudi J Ophthalmol. 2011;25:145-158. doi: 10.1016/j.sjopt.2011. 01.003.
  24. Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, Yamaike N, Yoshimura N. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion // Br J Ophthalmol. 2007;91:1644-1649. doi: 10.1136/bjo. 2007.118497.
  25. Shin HJ, Chung H, Kim HC. Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion // Acta Ophthalmol. 2011;89:e35-e40. doi: 10.1111/j.1755-3768.2010.02063.x.
  26. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH. Retinal vein occlusion study group: Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion // Graefes Arch Clin Exp Ophthalmol. 2011;249:183-192. doi: 10.1007/ s00417-010-1470-2.
  27. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography // Ophthalmology. 2013;120:1057-1063. doi: 10.1016/ j.ophtha. 2012.11.011.
  28. Sakamoto A, Tsujikawa A, Ota M, Yamaike N, Kotera Y, Miyamoto K, Kita M, Yoshimura N. Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion // Clin Experiment Ophthalmol. 2009;37:208-216. doi: 10.1111/j.1442-9071.2009.01914.x.
  29. Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES, Hess DJ, Rams I, Ball M, Gutierrez A, et al. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report // Ophthalmology. 1995;102:1425-1433. doi: 10.1016/S0161-6420(95)30849-4.
  30. Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion // Graefes Arch Clin Exp Ophthalmol. 1999;237:1024-1027. doi: 10.1007/ s004170050339.
  31. Ip MS, Scott IU, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5 // Arch Ophthalmol. 2009;127:1101-1114. doi: 10.1001/archophthalmol. 2009.234.
  32. Zhao L, Li B, Feng K, Han L, Ma Z, Liu Y. Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage // Curr Eye Res. 2015;40:752-756. doi: 10.3109/02713683.2014.952827.
  33. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion // Graefes Arch Clin Exp Ophthalmol. 2010;248:155-159. doi: 10.1007/s00417-009-1167-6.
  34. Hoeh AE, Ruppenstein M, Ach T, Dithmar S. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion // Graefes Arch Clin Exp Ophthalmol. 2010;248:1567-1572. doi: 10.1007/s00417-010-1419-5.
  35. Kang HM, Chung EJ, Kim YM, Koh HJ. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion // Graefes Arch Clin Exp Ophthalmol. 2013;251:501-508. doi: 10.1007/s00417-012-2067-8.
  36. Oishi A, Hata M, Shimozono M, Mandai M, Nishida A, Kurimoto Y. The significance of external limiting membrane status for visual acuity in age-related macular degeneration // Am J Ophthalmol. 2010;150:27-32. doi: 10.1016/j. ajo.2010.02.012.